1. Home
  2. GTX vs EWTX Comparison

GTX vs EWTX Comparison

Compare GTX & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Garrett Motion Inc.

GTX

Garrett Motion Inc.

HOLD

Current Price

$20.65

Market Cap

3.5B

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$30.45

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTX
EWTX
Founded
2018
2017
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.3B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
GTX
EWTX
Price
$20.65
$30.45
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$20.40
$39.00
AVG Volume (30 Days)
1.7M
899.6K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.56%
N/A
EPS Growth
20.63
N/A
EPS
0.49
N/A
Revenue
$3,584,000,000.00
N/A
Revenue This Year
$4.16
N/A
Revenue Next Year
$3.27
N/A
P/E Ratio
$13.47
N/A
Revenue Growth
3.14
N/A
52 Week Low
$9.58
$12.31
52 Week High
$21.42
$35.00

Technical Indicators

Market Signals
Indicator
GTX
EWTX
Relative Strength Index (RSI) 62.10 43.33
Support Level $17.17 $28.72
Resistance Level $20.53 $31.28
Average True Range (ATR) 0.55 1.52
MACD 0.11 -0.44
Stochastic Oscillator 68.61 4.93

Price Performance

Historical Comparison
GTX
EWTX

About GTX Garrett Motion Inc.

Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: